TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18816360

Group type: EXPERIMENTAL
Intervention: Videotaped self-modeling and positive feedback about father-infant interaction provided by specially trained nurses
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Videotaped self-modeling and positive feedback about father-infant interaction
Number of subjects: 81
Study: 17415601

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) imaging
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 20
Study: 15234503

Group type: EXPERIMENTAL
Intervention: Percutaneous Kirschner wires
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buried Kirschner wires
Number of subjects: 0
Study: 11724442

Group type: EXPERIMENTAL
Intervention: Antibodies to IFN-gamma
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Antibodies to TNF-alpha
Number of subjects: 45
Study: 9404216

Group type: EXPERIMENTAL
Intervention: CT scans performed at 40 mAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT scans performed at 60 mAs
Number of subjects: 0
Study: 8492200

Group type: EXPERIMENTAL
Intervention: Ibuprofen-codeine (400 mg ibuprofen + 60 mg codeine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 60
Study: 3819254

Group type: EXPERIMENTAL
Intervention: SHAPEDOWN program
Number of subjects: 66
Study: 30508936

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 200
Study: 27706551

Group type: EXPERIMENTAL
Intervention: Optimum Power Load (OPL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Traditional Strength-Power Periodization (TSP)
Number of subjects: 23
Study: 25355671

Group type: EXPERIMENTAL
Intervention: Common project-based European identity prime
Number of subjects: 206

Group type: COMPARATOR
Intervention: Common heritage-based European identity prime
Number of subjects: 206
Study: 24329692

Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS (active)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 10 Hz rTMS (active)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 59
Study: 20597358

Group type: EXPERIMENTAL
Intervention: Intervention group (received one session of psycho-education about self-complexity and kept daily records for one week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 40
Study: 18822909

Group type: EXPERIMENTAL
Intervention: Ligustrazine plus citicoline (group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ligustrazine alone (group B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Citicoline alone (group C)
Number of subjects: 300
Study: 17121048

Group type: EXPERIMENTAL
Intervention: Acupuncture in Siguan points combined with intravenous midazolam injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous midazolam injection
Number of subjects: 60
Study: 12541156

Group type: EXPERIMENTAL
Intervention: DCLHb (up to 1000 ml of a 10% diaspirin cross‐linked hemoglobin solution)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: DCLHb
Number of subjects: 121
Study: 10710206

Group type: EXPERIMENTAL
Intervention: IFN-alpha (3 MU subcutaneously every 24 hr)
Number of subjects: 256

Group type: COMPARATOR
Intervention: ZDV and ddC (control group)
Number of subjects: 256
Study: 9347091

Group type: EXPERIMENTAL
Intervention: i.v. human (h) CRF
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Multifaceted stress test
Number of subjects: 11

Group type: COMPARATOR
Intervention: Block I (baseline)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Block II (after 12 weeks of abstinence)
Number of subjects: 11
Study: 8445202

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (initial bolus of 30 mg/kg followed by infusion of 5.4 mg/kg/h over 23 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (naloxone or placebo)
Number of subjects: 0
Study: 3528240

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics plus elastic support bandages
Number of subjects: 47

Group type: COMPARATOR
Intervention: Elastic support bandages only
Number of subjects: 47
Study: 29550766

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg with loading dose (LD)
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg with loading dose (LD)
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg without loading dose (LD)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 996
Study: 27218418

Group type: EXPERIMENTAL
Intervention: Nonswallow procedure for nasogastric tube insertion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard nasogastric tube insertion)
Number of subjects: 80
Study: 24504006

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice-daily for 12 months
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 22146609

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional walking treatment (CWT)
Number of subjects: 32
Study: 20346183

Group type: EXPERIMENTAL
Intervention: Participatory return-to-work program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18652967

Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization exercise in addition to standard care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 16243131

Group type: EXPERIMENTAL
Intervention: 70 J/cm2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 100 J/cm2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 140 J/cm2
Number of subjects: 27

Group type: COMPARATOR
Intervention: All light doses (70, 100, 140 J/cm2)
Number of subjects: 27
Study: 12105366

Group type: EXPERIMENTAL
Intervention: Reduced cerebrovascular reactivity (rCVR) to acetazolamide
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal cerebrovascular reactivity (rCVR) to acetazolamide
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ICA or MCA occlusion with reduced rCVR
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lower rCVR and resting regional cerebral blood flow values
Number of subjects: 70
Study: 10485080

Group type: EXPERIMENTAL
Intervention: CAI with a standardized high fat meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: CAI fasting
Number of subjects: 12
Study: 7612530

Group type: EXPERIMENTAL
Intervention: Syntometrine
Number of subjects: 1000
Study: 3058374

Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (50 micrograms subcutaneously)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 5
Study: 28922786

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 6815

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 6815

Group type: COMPARATOR
Intervention: Observation (No IFN)
Number of subjects: 6815
Study: 28578654

Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance training (PRT) program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 72
Study: 26197801

Group type: EXPERIMENTAL
Intervention: Blended learning approach (combination of face-to-face and online/mobile learning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional face-to-face method (ten 2-hour classes)
Number of subjects: 0
Study: 23044732

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 37
Study: 21309847

Group type: EXPERIMENTAL
Intervention: Personalised 10‐year CVD risk estimates
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 194
Study: 19816272

Group type: EXPERIMENTAL
Intervention: Rotating cutters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piezoelectric terminals
Number of subjects: 0
Study: 16890114

Group type: EXPERIMENTAL
Intervention: EC-MPS 1,080 mg twice daily
Number of subjects: 154

Group type: COMPARATOR
Intervention: MMF 1,500 mg twice daily
Number of subjects: 154
Study: 15292101

Group type: EXPERIMENTAL
Intervention: 4 LNG rods (75 mg each) followed by 500 mg of TU by IM injection every 8 weeks for 24 weeks (Group I)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 4 LNG implants followed by 1000 mg of TU by IM injection every 8 weeks for 24 weeks (Group II)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 1000 mg of TU by IM injection every 8 weeks for 24 weeks (Group III)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison of groups I, II, and III
Number of subjects: 62
Study: 11308113

Group type: EXPERIMENTAL
Intervention: Train-the-trainer intervention for health promotion and risk reduction in pregnancy; 76 village women trained using low literacy techniques.
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned; preintervention survey serves as baseline.
Number of subjects: 187
Study: 9444444

Group type: COMPARATOR
Intervention: 5 mg of lubeluzole (1-hour intravenous infusion)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 10 mg of lubeluzole (1-hour intravenous infusion)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 15 mg of lubeluzole (1-hour intravenous infusion)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lubeluzole (various doses)
Number of subjects: 22
Study: 8197778

Group type: EXPERIMENTAL
Intervention: Lumpectomy followed by breast irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lumpectomy
Number of subjects: 0
Study: 3884188

Group type: EXPERIMENTAL
Intervention: D‐Ala2‐MePhe4‐met‐enkephalin‐O‐ol (DAMME)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 2
Study: 29956042

Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells (BM-MSC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Optimum post-infarction treatment (Control group)
Number of subjects: 26
Study: 24549094

Group type: EXPERIMENTAL
Intervention: 7.2% NaCl/6% hydroxyethyl starch 200/0.5 (HSH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl; control group)
Number of subjects: 40
Study: 22219409

Group type: EXPERIMENTAL
Intervention: CABG with concomitant pulmonary vein isolation (PVI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CABG with PVI
Number of subjects: 35
Study: 20557578

Group type: EXPERIMENTAL
Intervention: São Pedro do Sul (SPS) thermal water
Number of subjects: 17

Group type: COMPARATOR
Intervention: Purified water
Number of subjects: 17
Study: 18599019

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.4% plus prednisolone acetate 1% QID
Number of subjects: 546

Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1% QID alone
Number of subjects: 546
Study: 17726715

Group type: EXPERIMENTAL
Intervention: Designs with sample size reestimation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-size designs
Number of subjects: 0
Study: 15003920

Group type: EXPERIMENTAL
Intervention: Lower fat (LF, 27%) group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Modified fat (MF, 37%E) group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual diet (LF or MF)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Dietary fat targets achievement
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Dietary contributions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cuisine choices
Number of subjects: 63
Study: 10699908

Group type: EXPERIMENTAL
Intervention: Weekly continuation chemotherapy with rotating pairs of drugs (teniposide and cytarabine, vincristine and cyclophosphamide) with repeated reinduction with PVDA
Number of subjects: 297

Group type: COMPARATOR
Intervention: Weekly continuation chemotherapy with rotating pairs of drugs (teniposide and cytarabine, vincristine and cyclophosphamide) without repeated reinduction with PVDA
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT) instead of continued chemotherapy
Number of subjects: 297
Study: 9347435

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.3 mg/kg
Number of subjects: 60
Study: 1485054

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 4033109

Group type: EXPERIMENTAL
Intervention: Nonwoven microporous tape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonwoven microporous reinforced tape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gauze tape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyurethane tape
Number of subjects: 0
Study: 30536967

Group type: EXPERIMENTAL
Intervention: Presentation time of 84 ms for real objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unlimited viewing time for real objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation time of 84 ms for meaningless patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation time of 150 ms for meaningless patterns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unlimited viewing time for meaningless patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation times of 84 ms and 150 ms for meaningless patterns
Number of subjects: 0
Study: 29173822

Group type: EXPERIMENTAL
Intervention: Clinical and home-based physical activity program (PAP) and simple lymphatic drainage (SLD), administered twice a week for six weeks.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 52
Study: 25493545

Group type: EXPERIMENTAL
Intervention: SBC (Salient Beliefs Condition)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PC (Planning Condition)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CC (Combination Condition)
Number of subjects: 116

Group type: COMPARATOR
Intervention: NSBC (Non-Salient Beliefs Condition)
Number of subjects: 116
Study: 23297129

Group type: EXPERIMENTAL
Intervention: Thalidomide-prednisone
Number of subjects: 332

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 332
Study: 20229199

Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg disodium pamidronate, n=24)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg disodium pamidronate)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pamidronate and Placebo
Number of subjects: 39
Study: 19958945

Group type: EXPERIMENTAL
Intervention: Nerve monitoring of the EBSLN (group 1)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No nerve monitoring (group 2)
Number of subjects: 47
Study: 16490472

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg BID
Number of subjects: 13274

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 13274

Group type: COMPARATOR
Intervention: Nonselective NSAIDs (diclofenac 50 mg BID or naproxen 500 mg BID)
Number of subjects: 13274
Study: 14988517

Group type: EXPERIMENTAL
Intervention: Extract of Perilla frutescens enriched for rosmarinic acid (200 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Extract of Perilla frutescens enriched for rosmarinic acid (50 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Extract of Perilla frutescens enriched for rosmarinic acid (200 mg and 50 mg combined)
Number of subjects: 29
Study: 10751780

Group type: EXPERIMENTAL
Intervention: Local delivery of heparin at 40- or 100-psi infusion pressure
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Local delivery of heparin at 100 psi
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Local delivery of heparin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 57
Study: 9312717

Group type: EXPERIMENTAL
Intervention: Interval hypoxic training (IHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study: 8453959

Group type: EXPERIMENTAL
Intervention: New inhalation spacer device (Rondo) with salbutamol (Salbuvent)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Salbutamol (Ventoline) with Volumatic spacer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Salbutamol (Salbuvent) with conventional metered dose actuator
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: New inhalation spacer device (Rondo)
Number of subjects: 15
Study: 3518775

Group type: EXPERIMENTAL
Intervention: Theophylline (single dose, levels greater than 10 micrograms ml‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30035566

Group type: EXPERIMENTAL
Intervention: Doing everyday solitary activities (e.g., reading, watching TV)
Number of subjects: 2557

Group type: COMPARATOR
Intervention: Thinking for pleasure
Number of subjects: 2557
Study: 29067598

Group type: EXPERIMENTAL
Intervention: Religious Cognitive Behavioral Therapy (R-CBT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Conventional Cognitive Behavioral Therapy (C-CBT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 79
Study: 28531392

Group type: EXPERIMENTAL
Intervention: Nasointestinal feeding
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nasogastric feeding plus prokinetics (metoclopramide and erythromycin)
Number of subjects: 50
Study: 25299079

Group type: EXPERIMENTAL
Intervention: Remifentanil preconditioning (R3 group, 1.8 μg·kg(‐1)·min(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil preconditioning (R3 group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 40
Study: 23097240

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg b.i.d. for 6 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Safinamide (100 mg single dose)
Number of subjects: 14
Study: 20403374

Group type: EXPERIMENTAL
Intervention: LiSM intervention (n=52)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No-treatment control (n=49)
Number of subjects: 101
Study: 18936500

Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg three times daily, titrated to 40 mg and 80 mg as tolerated)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 15976803

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 12073066

Group type: EXPERIMENTAL
Intervention: Double running suture (DRS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Single running suture (SRS)
Number of subjects: 68
Study: 9821026

Group type: EXPERIMENTAL
Intervention: Out-patient treatment with low molecular weight heparin and oral anticoagulants, with daily attendance at the out-patient clinic.
Number of subjects: 523
Study: 7644189

Group type: EXPERIMENTAL
Intervention: Isoproterenol administration
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Head up tilt table test
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Treatment for vasovagal syncope
Number of subjects: 71
Study: 2504118

Group type: EXPERIMENTAL
Intervention: Mannitol cardioplegic solution (59.8 mmol/L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard cardioplegic solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mannitol cardioplegic solution
Number of subjects: 40
Study: 197443

Group type: EXPERIMENTAL
Intervention: ACTH4-10 (60 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30229989

Group type: EXPERIMENTAL
Intervention: Immunosuppression (IS) minimization (n = 31)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Immunosuppression (IS) free (n = 9)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Immunosuppression (IS) maintenance (n = 9)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: IS minimization
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Stable IS monotherapy 1 year after transplantation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Acute rejections
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Biopsy-proven findings disqualifying patients from IS withdrawal
Number of subjects: 69
Study: 28178149

Group type: EXPERIMENTAL
Intervention: Combination of peripheral nerve block and general anesthesia (NB + GA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia alone (GA)
Number of subjects: 120
Study: 25270758

Group type: EXPERIMENTAL
Intervention: WELLFOCUS PPT (11-week group positive psychology intervention)
Number of subjects: 37
Study: 23364128

Group type: EXPERIMENTAL
Intervention: Inter-dependent self-knowledge intervention (We passages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent self-knowledge intervention (I passages)
Number of subjects: 0
Study: 21771098

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream (HCT) applied twice daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pimecrolimus 1% cream (PIM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream (HCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream (HCT) and Pimecrolimus 1% cream (PIM)
Number of subjects: 0
Study: 19337726

Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 30
Study: 16816943

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.02 mg/kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15488446

Group type: EXPERIMENTAL
Intervention: High cognitive load with ego threat (CNS task)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Low cognitive load with processing and memorisation of colour nouns (CNS task)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: High cognitive load (CNS task)
Number of subjects: 119